Clinical trial · Interventional
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NCT02900157CI-TRIAL-00049432completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Durvalumab | Biological | Durvalumab | ALIAS |
| MEDI9090 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MEDI9090
- interventionNames
- Biological: MEDI9090
- Biological: Durvalumab
Primary outcomes (2)
- measure
- Number of subjects reporting infusion related reactions
- timeFrame
- First dose of study medication through 30 days after the first dose of study medication
- measure
- Number of subjects that develop changes in detectable antidrug antibodies to MEDI9090
- timeFrame
- First dose of study medication through 6 months after the last dose of study medication
Secondary outcomes (5)
- measure
- Individual MEDI9090 concentrations
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female subjects * 18 years and older * Must have histologic documentation of advanced solid tumors * Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option Exclusion Criteria: * Concurrent enrollment in another clinical study * Prior participation in clinical studies that include durvalumab alone or in combination * Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
References
Publications (0)
Data not yet available
No reference posted for this study.